26 September 2024 - BEAM AllianceNew York, From inside the UN buildings – Remko van LeeuwenJust a few hours ago the General Assembly of the UN has adopted a new declaration on fighting AMR. Regardless…read more >>
17 September 2024 - BEAM AllianceBEAM’s Reflection paper on General Pharmaceutical Legislation Revision: Taking Stock of the EU Parliament Position and Moving ForwardThe BEAM Alliance would like to reiterate its call for optimal PULL incentives designed to fit innovators’ needs based on…read more >>
24 October 2023 - BEAM AllianceBEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical LegislationWe call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…read more >>
05 September 2023 - BEAM AllianceBEAM Alliance is Launching a new Task Force to address Issues from the AMR Diagnostics SegmentThe new Task Force is gathering innovative SMEs operating in the AMR field and external experts.read more >>
16 June 2023 - BEAM AllianceBEAM’s reflection paper on the possible roles of DG HERAThe report represents an important step towards the implementation of a tangible solution to fix the AMR market. Although the…read more >>
23 May 2023 - BEAM AllianceBEAM’s statement on the EU Council Recommendation on AMRThe proposal examines AMR in a rather exhaustive way. It includes provisions on the need to strengthen national action plans,…read more >>
22 October 2024 - BioVersys AGBioVersys Joins EU-Funded RespiriNTM Programme to Accelerate Development of Its Broad-Spectrum Drug Candidates Against NTM Pulmonary DiseasesThe RespiriNTM project has received funding from the Innovative Health Initiative 2 Joint Undertaking (JU) under grant agreement No 853932.…read more >>
16 October 2024 - BioVersys AGBioversys Announces Last Patient Last Visit in BV100 Phase 2 Clinical Trial in Ventilator Associated Bacterial Pneumonia (VABP) and Provides a Business UpdateBV100 is a novel formulation of rifabutin suitable for intravenous administration, with a recently discovered novel mode of action showing…read more >>
10 October 2024 - BasileaStrong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this yearIsavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba®.read more >>
24 September 2024 - BasileaBasilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasisInvasive Candida infections are life-threatening complications for many hospitalized patients and associated with high mortality, and fosmanogepix offers a potential…read more >>
24 September 2024 - BioVersys AGBioVersys: Nature Reviews Highlights Significant Successes of Antibiotic Collaboration and Calls for Sustainable R&D Funding SchemesThe continued innovation for developing new antibiotics fighting AMR is crucial for modern medicine, in high- and low-income countries. There…read more >>
23 September 2024 - QureTech Bio ABQureTech Bio announces prestigious investment from KempestiftelsernaWith this financial support, QureTech Bio will be able to accelerate its research and development efforts of novel antibiotic treatments…read more >>
09 April 2024REVIVE Webinar: Progressing a discovery project – Criteria and challengeswith Ken Bradley, Global Head, Infectious Disease Discovery, Roche and Diarmaid Hughes, Professor of Medical Molecular Bacteriology, Uppsala University (Sweden)read more >>
21 March 2024BEAM webinar – BioAster: Novel technologies with an AI-facilitated approachBEAM is excited to host a series of webinars setup by its Associated Organizations.read more >>
18 March 2024BIO-Europe Spring ® 2024 – 18th Annual International Partnering ConferenceReconnecting and facilitating global partnershipsread more >>
06 March 20248th AMR ConferenceThe AMR conference is a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and…read more >>
27 February 2024GARDP Webinar – What does the future look like if pull incentives to support antibiotic R&D are insufficient?This webinar will discuss potential solutions, including support for non-profit R&D organizations, to get new treatments to patients in the…read more >>
06 February 2024Antimicrobial Chemotherapy Conference (ACC) 2024 – Free Online ConferenceThis virtual conference is jointly organised by GARDP and BSAC.read more >>
22 January 2024REVIVE Webinar – What do the various non-commercial actors in the antibiotics R&D ecosystem do?with Erin Duffy (CARB-X), Peter Beyer (GARDP) and Laura Marin (JPIAMR).read more >>
07 December 2023GARDP: An innovative public health approach to counter AMRThis webinar will present GARDP’s new five-year strategy, but also highlight our achievements over the past five years in developing…read more >>
16 November 2023Emerging Antimicrobials and Diagnostics in AMR 2023 (EADA 2023)EADA 2023 is the 11th AMR Insights International Matchmaking Symposium on row. The 1,5 day event provides an overview of…read more >>